Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are a cornerstone of systemic therapy for clear cell renal cell carcinoma (ccRCC), yet response rates remain variable and predictive biomarkers are lacking. This study aimed to determine whether baseline levels of myeloid-derived suppressor cells (MDSCs), especially monocytic (M-MDSC) and polymorphonuclear (PMN-MDSC) subtypes, could predict ICI response in ccRCC patients.

Methods

In this prospective cohort study, 20 ccRCC patients receiving ICI-based therapy for at least 3 months were enrolled. Peripheral blood mononuclear cells were collected before and after treatment to quantify total MDSCs, M-MDSCs, and PMN-MDSCs via flow cytometry. Additional clinical variables, including blood cell counts and metabolic profiles, were asses

SUBMITTER: Jin Y 

PROVIDER: S-EPMC12408328 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature